 |
|
|
| |
SAFETY AND EFFICACY OF THE ALL-ORAL REGIMEN OF MK-5172 / MK-8742 ± RIBAVIRIN IN TREATMENT-NAIVE, NONCIRRHOTIC PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION: THE C-WORTHy STUDY
|
| |
| |
Reported by Jules Levin
Presented at the 49th Annual Meeting of the European Association for the Study of the Liver
April 9-13, 2014, London, United Kingdom
Christophe Hezode, Lawrence Serfaty, John M. Vierling, Marcelo Kugelmas,
Brian Pearlman, William Sievert, Wayne Ghesquiere, Eli Zuckerman,
Fredrik Sund, Anita Howe, Melissa Shaughnessy, Peggy Hwang,
Janice Wahl, Michael N. Robertson, Barbara Haber
|
| |
|
|
|
|
|
